The first in the world! my country has successfully mastered another key technology
Recently, the China Institute of Atomic Energy cooperated with Qinshan Nuclear Power to use independently developed low-enriched uranium targets for reactor irradiation to produce molybdenum-99 samples that meet medical requirements and have a nuclear purity of 99%, and successfully passed on-site acceptance. This marks that China has become the first country in the world to master the key technology of producing medical fission molybdenum-99 from commercial nuclear power plant reactors. It is expected to reverse my country's long-term dependence on imports of medical molybdenum-99 and realize the localization of medical molybdenum-99.
Technetium-99m is known as the "diagnostic expert" of nuclear medicine. It can be used for imaging and functional examination of body organs, and plays a very important role in the diagnosis of malignant tumors, cardiovascular diseases, etc. According to statistics, more than 40 million people around the world use technetium-99m for medical diagnosis every year, and medical molybdenum-99 is the best source of technetium-99m.
According to reports, the research team, on the basis of fully mastering the preparation technology of low-enriched uranium targets, proposed a new idea of "using high-neutron flux commercial CANDU reactors to irradiate low-enriched uranium targets to produce medical molybdenum-99", and has successively conquered applicable Using key technologies such as the design and preparation of low-enriched uranium targets for Kandu reactor irradiation, target dissolution, fission molybdenum-99 extraction, and process equipment development, we successfully obtained molybdenum-99 samples that meet medical requirements and provided the basis for my country's independent engineering production Medical fission molybdenum-99 has laid the technical foundation.
